Please assess the completion status of the following clinical trial:

Trial Title: Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who provide written informed consent before the trial, and fully understand the trial content, process and possible adverse reactions.~2. Participants who are willing and able to comply with the protocol for treatment plan, virological testing, laboratory testing and other study procedures.~3. Male or female participants aged 18-75 (including 18 and 75 years old).~4. Confirmed SARS-CoV-2 infection 120 hours prior to randomization.~5. Initial onset of COVID-19 symptoms/signs within 48 hours before randomization.~6. Fertile participants must agree to take effective contraceptive measures.~Exclusion Criteria:~1. Patients with severe or critical COVID-19 who currently require hospitalization, or patients who are expected to develop into severe or critical disease and require hospitalization within 48h after randomization.~2. Difficulty swallowing or a history of gastrointestinal diseases that seriously affect drug absorption.~3. Active liver disease, or obvious abnormal liver function (ALT or AST ≥ 3ULN, or total bilirubin ≥ 2ULN).~4. WBC \>1ULN, or NEU \<0.5ⅹ109/L.~5. Receiving dialysis or have known moderate to severe renal impairment (eGFR\<60mL/min/1.73m2).~6. Other suspected or confirmed systemic infections.~7. Current or expected use of strong CYP3A4 inducers, inhibitors or medications that are highly dependent on CYP3A4 or CYP2C19 for clearance.~8. Prior or anticipated receipt of any vaccine within 28 days prior to enrollment and during study period.~9. Use of antivirals against SARS-CoV-2 within 7 days prior to enrollment.~10. Weight≤40kg.~11. Pregnant, lactating women or those with a positive pregnancy test (sterilized or postmenopausal women may not have a pregnancy test).~12. Previous administration with any investigational drug within 3 months before the study drug administration.~13. Participants who are judged by the investigator to be unsuitable to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- RAY1216 (Type: EXPERIMENTAL): Participants received 400mg RAY1216 tablet orally three times daily for 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received 400mg placebo orally three times daily for 5 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).